Farzad Khademi - Department of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
Amirhossein Sahebkar - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

This updated systematic review and meta-analysis follows two aims: ۱) to assess Mycobacterium tuberculosis (M. tuberculosis) antibiotic resistance in Iran from ۲۰۱۳ to ۲۰۲۰ and, ۲) to assess the trend of resistance from ۱۹۹۹ to ۲۰۲۰. Several national and international databases were systematically searched through MeSH extracted keywords to identify ۴۱ published studies addressing drug-resistant M. tuberculosis in Iran. Meta-analysis was done based on the PRISMA protocols using Comprehensive Meta-Analysis software. The average prevalence of resistance to first- and second-line anti-TB drugs, multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) in new and previously treated tuberculosis (TB) cases in Iran during ۲۰۱۳–۲۰۲۰ were as follows: isoniazid ۶.۹%, rifampin ۷.۹%, ethambutol ۵.۷%, pyrazinamide ۲۰.۴%, para-aminosalicylic acid ۴.۶%, capreomycin ۱.۷%, cycloserine ۱.۸%, ethionamide ۱۱.۳%, ofloxacin ۱.۵%, kanamycin ۳.۸%, amikacin ۲.۲%, MDR-TB ۶.۳% and XDR-TB ۰.۹%. Based on the presented data, M. tuberculosis resistance to first- and second-line anti-TB drugs, as well as MDR-TB, was low during ۲۰۱۳–۲۰۲۰ in Iran. Furthermore, there was a declining trend in TB drug resistance from ۱۹۹۹ to ۲۰۲۰. Hence, to maintain the current decreasing trend and to control and eliminate TB infection in Iran, continuous monitoring of resistance patterns is recommended.

Antibiotic Iran Meta, analysis Mycobacterium tuberculosis Resistance